Literature DB >> 3130683

Susceptibility and natural resistance of Trypanosoma cruzi strains to drugs used clinically in Chagas disease.

L S Filardi1, Z Brener.   

Abstract

The susceptibility and natural resistance to two nitroheterocyclic derivatives used clinically in Chagas disease (nifurtimox and benznidazole) were investigated in 47 Trypanosoma cruzi strains isolated from human patients, domestic vectors and sylvatic reservoirs or vectors. A large gradient of drug efficacy from 0% to 100% was detected. Drug susceptibility apparently related to geographical distribution of some T. cruzi strains was also observed. Drug resistance was identified among T. cruzi populations isolated from sylvatic vectors from an area where autochthonous human Chagas disease does not exist. Thus, natural drug-resistance of sylvatic strains might be a way of introducing this character into a T. cruzi domestic cycle. Most of the 47 studied strains were either sensitive or resistant to both compounds, an intriguing finding considering that nifurtimox and benznidazole apparently have different mechanisms of action against T. cruzi.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3130683     DOI: 10.1016/0035-9203(87)90020-4

Source DB:  PubMed          Journal:  Trans R Soc Trop Med Hyg        ISSN: 0035-9203            Impact factor:   2.184


  126 in total

1.  Proinflammatory and cytotoxic effects of hexadecylphosphocholine (miltefosine) against drug-resistant strains of Trypanosoma cruzi.

Authors:  Victor B Saraiva; Daniel Gibaldi; José O Previato; Lucia Mendonça-Previato; Marcelo T Bozza; Célio G Freire-De-Lima; Norton Heise
Journal:  Antimicrob Agents Chemother       Date:  2002-11       Impact factor: 5.191

2.  Arylimidamide DB766, a potential chemotherapeutic candidate for Chagas' disease treatment.

Authors:  Denise da Gama Jaén Batista; Marcos Meuser Batista; Gabriel Melo de Oliveira; Patrícia Borges do Amaral; Joseli Lannes-Vieira; Constança Carvalho Britto; Angela Junqueira; Marli Maria Lima; Alvaro José Romanha; Policarpo Ademar Sales Junior; Chad E Stephens; David W Boykin; Maria de Nazaré Correia Soeiro
Journal:  Antimicrob Agents Chemother       Date:  2010-05-10       Impact factor: 5.191

3.  New drugs for neglected infectious diseases: Chagas' disease.

Authors:  Fabiana S Machado; Herbert B Tanowitz; Mauro M Teixeira
Journal:  Br J Pharmacol       Date:  2010-05       Impact factor: 8.739

4.  Drug Susceptibility of Genetically Engineered Trypanosoma cruzi Strains and Sterile Cure in Animal Models as a Criterion for Potential Clinical Efficacy of Anti-T. cruzi Drugs.

Authors:  Julio A Urbina; James H McKerrow
Journal:  Antimicrob Agents Chemother       Date:  2015-12       Impact factor: 5.191

5.  Vaccine-Linked Chemotherapy Improves Benznidazole Efficacy for Acute Chagas Disease.

Authors:  Kathryn Jones; Leroy Versteeg; Ashish Damania; Brian Keegan; April Kendricks; Jeroen Pollet; Julio Vladimir Cruz-Chan; Fabian Gusovsky; Peter J Hotez; Maria Elena Bottazzi
Journal:  Infect Immun       Date:  2018-03-22       Impact factor: 3.441

6.  The Anti-Trypanosoma cruzi activity of posaconazole in a murine model of acute Chagas' disease is less dependent on gamma interferon than that of benznidazole.

Authors:  Marcela L Ferraz; Ricardo T Gazzinelli; Rosana O Alves; Julio A Urbina; Alvaro J Romanha
Journal:  Antimicrob Agents Chemother       Date:  2007-01-12       Impact factor: 5.191

7.  Buthionine sulfoximine increases the toxicity of nifurtimox and benznidazole to Trypanosoma cruzi.

Authors:  Mario Faundez; Laura Pino; Paula Letelier; Carla Ortiz; Rodrigo López; Claudia Seguel; Jorge Ferreira; Mario Pavani; Antonio Morello; Juan Diego Maya
Journal:  Antimicrob Agents Chemother       Date:  2005-01       Impact factor: 5.191

8.  The reservosomes of epimastigote forms of Trypanosoma cruzi: occurrence during in vitro cultivation.

Authors:  R C Figueiredo; M Steindel; M J Soares
Journal:  Parasitol Res       Date:  1994       Impact factor: 2.289

9.  Benznidazole therapy during acute phase of Chagas disease reduces parasite load but does not prevent chronic cardiac lesions.

Authors:  Ivo Santana Caldas; André Talvani; Sérgio Caldas; Cláudia Martins Carneiro; Marta de Lana; Paulo Marcos da Matta Guedes; Maria Terezinha Bahia
Journal:  Parasitol Res       Date:  2008-05-04       Impact factor: 2.289

10.  Nonpeptidic tetrafluorophenoxymethyl ketone cruzain inhibitors as promising new leads for Chagas disease chemotherapy.

Authors:  Katrien Brak; Iain D Kerr; Kimberly T Barrett; Nobuhiro Fuchi; Moumita Debnath; Kenny Ang; Juan C Engel; James H McKerrow; Patricia S Doyle; Linda S Brinen; Jonathan A Ellman
Journal:  J Med Chem       Date:  2010-02-25       Impact factor: 7.446

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.